Athira Pharma (NASDAQ:ATHA – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01), MarketWatch Earnings reports. NASDAQ ATHA opened at $8.28 on Friday. Athira Pharma has a 52-week low of $7.56 and a 52-week high of $23.64. The company […]
Athira Pharma (NASDAQ:ATHA – Get Rating) announced its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.01), MarketWatch Earnings reports. Shares of Athira Pharma stock opened at $8.28 on Friday. Athira Pharma has a 1 year low of $7.56 and a […]
Share:
SEATTLE, Dec. 14, 2020 (GLOBE NEWSWIRE) Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Kelly A. Romano to its Board of Directors. Ms. Romano is the Founder and Chief Executive Officer of BlueRipple Capital, LLC, a consultancy firm for global technology companies. As we expanded our Board, we sought a candidate who would help us best serve shareholders as we work towards making new treatments available for patients through the continued advancement of our Phase 2/3 clinical studies for ATH-1017 in Alzheimer s disease, said Leen Kawas, Ph.D., President and Chief Executive Officer at Athira. Kelly has a track record of operational success and an aptitude for understanding growing companies as we continue to drive the business forward.